Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsConstruction in ProgressCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Payables (2017 - 2026)

Dr Reddys Laboratories has reported Payables over the past 10 years, most recently at $1.0 billion for Q1 2026.

  • For Q1 2026, Payables rose 128.39% year-over-year to $1.0 billion; the TTM value through Mar 2026 reached $1.0 billion, up 128.39%, while the annual FY2026 figure was $1.0 billion, 17.44% up from the prior year.
  • Payables for Q1 2026 was $1.0 billion at Dr Reddys Laboratories, up from $443.3 million in the prior quarter.
  • Over five years, Payables peaked at $1.0 billion in Q1 2026 and troughed at $411.6 million in Q1 2023.
  • A 5-year average of $618.6 million and a median of $525.5 million in 2024 define the central range for Payables.
  • Biggest five-year swings in Payables: crashed 41.22% in 2023 and later surged 128.39% in 2026.
  • Year by year, Payables stood at $700.2 million in 2022, then crashed by 41.22% to $411.6 million in 2023, then grew by 27.68% to $525.5 million in 2024, then dropped by 15.65% to $443.3 million in 2025, then surged by 128.39% to $1.0 billion in 2026.
  • Business Quant data shows Payables for RDY at $1.0 billion in Q1 2026, $443.3 million in Q1 2025, and $525.5 million in Q1 2024.